FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2910331343> ?p ?o ?g. }

• W2910331343 endingPage "1210" @default.
• W2910331343 startingPage "1200" @default.
• W2910331343 abstract "Cancer vaccines composed of tumor-associated antigens (TAAs) and toll-like receptor (TLR) agonists have shown promising antitumor efficacy in preclinical studies by generating antigen-specific CD8 T cells, but translation of cancer vaccines to the clinic has been limited due to variables responses and development of resistance. The tumor microenvironment deploys various immune escape mechanisms that neutralize CD8 T cell-mediated tumor rejection. Therefore, we hypothesized that modulation of the tumor microenvironment can augment CD8 T cell activation and enhance therapeutic efficacy of cancer vaccines. To accomplish this, we aimed to eliminate immune suppressive cells and block their inhibitory signaling. Combination of the tyrosine kinase inhibitor (TKI) sunitinib with a nanoparticle-based cancer vaccine (nanovaccine) resulted in the reduction of immune-suppressive myeloid-derived suppressive cells (MDSCs) and regulatory T cells (Tregs). Blockade of programmed death-ligand 1 (PD-L1) using anti-PD-L1 antibody was used to reduce CD8 T cell exhaustion. Combination of nanovaccine+sunitinib+PD-L1 antibody treatment reduced PD-L1high M2 macrophages and MDSCs and upregulated activation of CD8 T cells in the tumor. Nanovaccine+sunitinib+PD-L1 antibody treatment also stimulated antigen-specific CD8 T cell response, which led to improved therapeutic efficacy in MB49 and B16F10 murine tumor models. These results suggest that modulation of tumor microenvironment using sunitinib and PD-L1 blockade can significantly enhance the antitumor efficacy of cancer nanovaccine." @default.
• W2910331343 created "2019-01-25" @default.
• W2910331343 creator A5007174878 @default.
• W2910331343 creator A5009925619 @default.
• W2910331343 creator A5050995173 @default.
• W2910331343 creator A5052400971 @default.
• W2910331343 creator A5053465014 @default.
• W2910331343 creator A5076681768 @default.
• W2910331343 creator A5078796555 @default.
• W2910331343 date "2019-01-08" @default.
• W2910331343 modified "2023-10-16" @default.
• W2910331343 title "Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine" @default.
• W2910331343 cites W1586699825 @default.
• W2910331343 cites W1602332990 @default.
• W2910331343 cites W1905971117 @default.
• W2910331343 cites W1913780655 @default.
• W2910331343 cites W1971174943 @default.
• W2910331343 cites W1976358776 @default.
• W2910331343 cites W1979152114 @default.
• W2910331343 cites W1984198270 @default.
• W2910331343 cites W1987446429 @default.
• W2910331343 cites W1991701295 @default.
• W2910331343 cites W2004150448 @default.
• W2910331343 cites W2014306509 @default.
• W2910331343 cites W2016356714 @default.
• W2910331343 cites W2016732129 @default.
• W2910331343 cites W2026506816 @default.
• W2910331343 cites W2042108941 @default.
• W2910331343 cites W2049481178 @default.
• W2910331343 cites W2078683291 @default.
• W2910331343 cites W2080097957 @default.
• W2910331343 cites W2081498322 @default.
• W2910331343 cites W2087032263 @default.
• W2910331343 cites W2091463916 @default.
• W2910331343 cites W2092921437 @default.
• W2910331343 cites W2100143031 @default.
• W2910331343 cites W2101653483 @default.
• W2910331343 cites W2108855090 @default.
• W2910331343 cites W2117253810 @default.
• W2910331343 cites W2122099202 @default.
• W2910331343 cites W2126882378 @default.
• W2910331343 cites W2136859769 @default.
• W2910331343 cites W2139064671 @default.
• W2910331343 cites W2144733364 @default.
• W2910331343 cites W2146774792 @default.
• W2910331343 cites W2147377038 @default.
• W2910331343 cites W2149436029 @default.
• W2910331343 cites W2168530155 @default.
• W2910331343 cites W2170651277 @default.
• W2910331343 cites W2171369497 @default.
• W2910331343 cites W2177405394 @default.
• W2910331343 cites W2237699600 @default.
• W2910331343 cites W2274704822 @default.
• W2910331343 cites W2307487014 @default.
• W2910331343 cites W2326365831 @default.
• W2910331343 cites W2337686938 @default.
• W2910331343 cites W2517416985 @default.
• W2910331343 cites W2550267433 @default.
• W2910331343 cites W2566550757 @default.
• W2910331343 cites W2567701218 @default.
• W2910331343 cites W2583745495 @default.
• W2910331343 cites W2600122482 @default.
• W2910331343 cites W2743361508 @default.
• W2910331343 cites W2755073646 @default.
• W2910331343 cites W2765445021 @default.
• W2910331343 cites W2782007611 @default.
• W2910331343 cites W2791126460 @default.
• W2910331343 cites W2791406043 @default.
• W2910331343 cites W2891140299 @default.
• W2910331343 cites W2895407555 @default.
• W2910331343 doi "https://doi.org/10.1021/acs.molpharmaceut.8b01165" @default.
• W2910331343 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30620878" @default.
• W2910331343 hasPublicationYear "2019" @default.
• W2910331343 type Work @default.
• W2910331343 sameAs 2910331343 @default.
• W2910331343 citedByCount "29" @default.
• W2910331343 countsByYear W29103313432019 @default.
• W2910331343 countsByYear W29103313432020 @default.
• W2910331343 countsByYear W29103313432021 @default.
• W2910331343 countsByYear W29103313432022 @default.
• W2910331343 countsByYear W29103313432023 @default.
• W2910331343 crossrefType "journal-article" @default.
• W2910331343 hasAuthorship W2910331343A5007174878 @default.
• W2910331343 hasAuthorship W2910331343A5009925619 @default.
• W2910331343 hasAuthorship W2910331343A5050995173 @default.
• W2910331343 hasAuthorship W2910331343A5052400971 @default.
• W2910331343 hasAuthorship W2910331343A5053465014 @default.
• W2910331343 hasAuthorship W2910331343A5076681768 @default.
• W2910331343 hasAuthorship W2910331343A5078796555 @default.
• W2910331343 hasConcept C121608353 @default.
• W2910331343 hasConcept C126322002 @default.
• W2910331343 hasConcept C147483822 @default.
• W2910331343 hasConcept C154317977 @default.
• W2910331343 hasConcept C159654299 @default.
• W2910331343 hasConcept C167672396 @default.
• W2910331343 hasConcept C170493617 @default.
• W2910331343 hasConcept C185592680 @default.
• W2910331343 hasConcept C202751555 @default.

• next